We were featured in a Deloitte report on transforming the future of clinical development in February, and are pleased that this was covered in a guest column in Clinical Leader.
"During the last decade, biopharmaceutical companies have successfully brought many breakthrough treatments to market. Still, industry stakeholders often say the current high-risk, high-cost R&D model is unsustainable..."
Read more at ClinicalLeader.com.